Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lübbert

Showing results (41-50 of 248) with videos related to

Pageof 25
Sort By:
Clinical Epigenetics|January 25, 2011
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyJulia M Wagner, Björn Hackanson, Michael Lübbert, et al.
Clinical Immunology (Orlando, Fla.)|October 31, 2003
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDSGiuseppe Leone, Maria Teresa Voso, Luciana Teofili, et al.
Leukemia|May 7, 2021
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapiesJulia Stomper, John Charles Rotondo, Gabriele Greve, et al.
Leukemia Research|September 16, 2005
Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instabilityPeter S Haas, Pierre Wijermans, Gregor Verhoef, et al.
Haematologica|November 4, 2006
Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approachesBarbara Deschler, Theo de Witte, Roland Mertelsmann, et al.
Pharmazie in Unserer Zeit|April 29, 2010
[Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors]Michael Daskalakis, Nadja Blagitko-Dorfs, Björn Hackanson, et al.
Advances in Therapy|November 17, 2021
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid LeukemiaValeria Santini, Michael Lübbert, Agnieszka Wierzbowska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemiaMichael Lübbert, Hartmut Bertz, Michael Josef Müller, et al.
International Journal of Cancer|November 8, 2025
DNA methyltransferase inhibitors in hematological malignancies and solid tumorsValentin Wenger, Guillermo Garcia-Manero, Robert Zeiser, et al.
Annals of Hematology|November 10, 2020
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case reportHannah Schüller, Franziska Klein, Michael Lübbert, et al.
Pageof 25

Showing results (41-50 of 248) with videos related to

Sort By:
Pageof 25
Clinical Epigenetics|January 25, 2011
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyJulia M Wagner, Björn Hackanson, Michael Lübbert, et al.
Clinical Immunology (Orlando, Fla.)|October 31, 2003
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDSGiuseppe Leone, Maria Teresa Voso, Luciana Teofili, et al.
Leukemia|May 7, 2021
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapiesJulia Stomper, John Charles Rotondo, Gabriele Greve, et al.
Leukemia Research|September 16, 2005
Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instabilityPeter S Haas, Pierre Wijermans, Gregor Verhoef, et al.
Haematologica|November 4, 2006
Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approachesBarbara Deschler, Theo de Witte, Roland Mertelsmann, et al.
Pharmazie in Unserer Zeit|April 29, 2010
[Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors]Michael Daskalakis, Nadja Blagitko-Dorfs, Björn Hackanson, et al.
Advances in Therapy|November 17, 2021
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid LeukemiaValeria Santini, Michael Lübbert, Agnieszka Wierzbowska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemiaMichael Lübbert, Hartmut Bertz, Michael Josef Müller, et al.
International Journal of Cancer|November 8, 2025
DNA methyltransferase inhibitors in hematological malignancies and solid tumorsValentin Wenger, Guillermo Garcia-Manero, Robert Zeiser, et al.
Annals of Hematology|November 10, 2020
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case reportHannah Schüller, Franziska Klein, Michael Lübbert, et al.
Pageof 25